Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

Jazz Pharmaceuticals plc announced the US Food and Drug Administration (FDA) accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Ziihera (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive ...

GLP-1 RAs to assist with weight loss have exploded in popularity. Researchers are working to identify which patients will benefit from them and their associated risks.

Jazz Pharmaceuticals has claimed FDA approval for its HER2-directed bispecific antibody Ziihera as a treatment for biliary tract cancer (BTC), the first in a series of potential indications that the ...

Oncologists are raising alarms as the American Cancer Society reports a concerning increase in cancer cases and deaths among ...

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

Ziihera is the first dual HER2-targeted bispecific antibody approved in the U.S. for HER2-positive biliary tract cancer ...